BHVN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-1.234

-33.28%

-1.247

-42.53%

-1.131

-41.68%

Estimates Revision

The market is revising Downward the revenue expectations for Biohaven Ltd. (BHVN) for FY2025, with the revenue forecasts being adjusted by -49.46% over the past three months. During the same period, the stock price has changed by -27.39%.

Revenue Estimates for FY2025

Revise Downward

-49.46%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-13.96%

In Past 3 Month

Stock Price

Go Down

-27.39%

In Past 3 Month

13 Analyst Rating

Wall Street analysts forecast BHVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHVN is 16.82 USD with a low forecast of 9.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

5 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

9.00

Averages

16.82

High

30.00

Current: 0.000

Low

9.00

Averages

16.82

High

30.00

Stifel

Paul Matteis

Buy

maintain

2025-12-26

Reason

Stifel

Paul Matteis

Price Target

2025-12-26

maintain

Buy

Reason

Stifel analyst Paul Matteis is reiterating a Buy rating on Xenon Pharmaceuticals (XENE) following Biohaven's (BHVN) Kv7 drug failing in a study in major depression disorder as the firm continues to believe that there's limited evidence suggesting that Biohaven's Kv7 compound BHV-7000 will be as efficacious as XEN1101. The firm, which continues to like Xenon shares heading into a pivotal 2026 with Phase 3 data for '1101 in FOS, keeps a Buy rating on Xenon shares.

H.C. Wainwright

Neutral

maintain

$11

2025-12-26

Reason

H.C. Wainwright

Price Target

$11

2025-12-26

maintain

Neutral

Reason

H.C. Wainwright is not surprised by Biohaven's (BHVN) BHV-7000 study failure in major depressive disorder. However, investors have largely been focused on the company's readout in focal onset seizures, the analyst tells investors in a research note. H.C. Wainwright believes the depression failure reinforces its caution headed into the seizures readout. It adds that Biohaven's miss does not meaningfully influence its expectations for Xenon Pharmaceuticals' (XENE) azetukalner Phase 3 study in major depressive disorder. H.C. Wainwright keeps a Neutral rating on Biohaven with an $11 price target.

William Blair

Myles Minter

Market Perform

maintain

2025-12-26

Reason

William Blair

Myles Minter

Price Target

2025-12-26

maintain

Market Perform

Reason

William Blair analyst Myles Minter keeps a Market Perform rating on Biohaven after the company's Phase II study miss for BHV-7000 in major depression disorder. While disappointing, William Blair was cautious into the study given difficulties in depression clinical trial execution and placebo creep in trials over recent years, the analyst tells investors in a research note. The firm looks to the pivotal data for BHV-7000 in focal onset epilepsy in first half of 2026 as a key data point to determine if the extended-release formulation of the drug is an active formulation. It sees limited negative readthrough to Xenon Pharmaceuticals' (XENE) depression study from Biohaven's miss.

Citi

Samantha Semenkow

Buy

maintain

$14

2025-12-26

Reason

Citi

Samantha Semenkow

Price Target

$14

2025-12-26

maintain

Buy

Reason

Citi analyst Samantha Semenkow keeps a Buy rating on Biohaven with a $14 price target after the company announced the Phase 2 study for BHV-7000 in major depressive disorder did not meet its primary endpoint. While "disappointing," expectations for the readout very low, the analyst tells investors in a research note. Citi believes investors are more focused on the upcoming Phase 3 epilepsy data for BHV- 7000 expected in the first half of 2026. The firm sees a higher chance of success for this study. Biohaven shares in premarket trading are down 14% to $9.30.

Jefferies

Buy

maintain

$65

2025-12-26

Reason

Jefferies

Price Target

$65

2025-12-26

maintain

Buy

Reason

Jefferies was "unsurprised" to see Biohaven's (BHVN) report mixed Phase 2 data in major depressive disorder, but believes the drug profile differs fundamentally from Xenon Pharmaceuticals' (XENE) own oral Kv7 drug, azetukalner, which has already shown best-in-class efficacy in focal epilepsy and a positive signal in MDD, the analyst tells investors. Opakalim's MDD failure should be idiosyncratic, rather than a Kv7 class effect, argues the analyst, who thinks any Xenon stock weakness could be a buying opportunity into the company's Phase 3 epilepsy data due in early 2026. Jefferies keeps a Buy rating and $65 price target on Xenon shares.

H.C. Wainwright

Buy

Neutral

downgrade

$30 -> $11

2025-12-03

Reason

H.C. Wainwright

Price Target

$30 -> $11

2025-12-03

downgrade

Buy

Neutral

Reason

H.C. Wainwright downgraded Biohaven to Neutral from Buy with a price target of $11, down from $30. The company reduced operating expenses and raised additional funding, "but now needs clear wins to keep the pipeline moving," the analyst tells investors in a research note. The firm sees a low likelihood that opakalim's Phase 3 data will exceed, or even match, azetukalner's efficacy. It downgrades the shares seeing "fewer ways to win."

Valuation Metrics

The current forward P/E ratio for Biohaven Ltd (BHVN.N) is -2.51, compared to its 5-year average forward P/E of -4.29. For a more detailed relative valuation and DCF analysis to assess Biohaven Ltd 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-4.29

Current PE

-2.51

Overvalued PE

-2.61

Undervalued PE

-5.97

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.48

Current EV/EBITDA

-3.05

Overvalued EV/EBITDA

-0.72

Undervalued EV/EBITDA

-6.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

64096.20

Current PS

0.00

Overvalued PS

288755.42

Undervalued PS

-160563.03

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 3226.99% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 3226.99% over the last month.

Sold

Bought

BHVN News & Events

Events Timeline

No data

News

1.0

01-07PRnewswire

Biohaven CEO Vlad Coric to Present at J.P. Morgan Healthcare Conference on January 12, 2026

1.0

01-07Newsfilter

Biohaven CEO Vlad Coric to Present at J.P. Morgan Healthcare Conference on January 12, 2026

5.0

01-06NASDAQ.COM

VHT ETF Sees Notable Insider Buying in Fortrea and Biohaven Holdings

People Also Watch

Frequently Asked Questions

What is Biohaven Ltd (BHVN) stock price today?

The current price of BHVN is 11.11 USD — it has decreased -2.2 % in the last trading day.

What is Biohaven Ltd (BHVN)'s business?

Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.

What is the price predicton of BHVN Stock?

What is Biohaven Ltd (BHVN)'s revenue for the last quarter?

Biohaven Ltd revenue for the last quarter amounts to -169.38M USD, decreased -4.93 % YoY.

What is Biohaven Ltd (BHVN)'s earnings per share (EPS) for the last quarter?

Biohaven Ltd. EPS for the last quarter amounts to -145729000.00 USD, increased 2.71 % YoY.

What changes have occurred in the market's expectations for Biohaven Ltd (BHVN)'s fundamentals?

How many employees does Biohaven Ltd (BHVN). have?

Biohaven Ltd (BHVN) has 256 emplpoyees as of January 11 2026.

What is Biohaven Ltd (BHVN) market cap?

Today BHVN has the market capitalization of 1.43B USD.